Barinthus Biotherapeutics plc

DB:2AB Stock Report

Market Cap: €43.0m

Barinthus Biotherapeutics Past Earnings Performance

Past criteria checks 0/6

Barinthus Biotherapeutics's earnings have been declining at an average annual rate of -25.6%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 8% per year.

Key information

-25.6%

Earnings growth rate

154.1%

EPS growth rate

Biotechs Industry Growth-14.6%
Revenue growth rate8.0%
Return on equity-36.3%
Net Margin-386.3%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Barinthus Biotherapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:2AB Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2415-5841-7
30 Jun 240-6428-3
31 Mar 240-7134-3
31 Dec 231-7340-3
30 Sep 237-774734
30 Jun 2313-553520
31 Mar 2330-1515-1
31 Dec 224556-1
30 Sep 223811-4-2
30 Jun 2232-18-4
31 Mar 2215-3327-4
31 Dec 210-5125-4
30 Sep 211-4623-3
30 Jun 214-4123-4
31 Mar 214-2911-4
31 Dec 205-1810-3
31 Dec 197-213-3

Quality Earnings: 2AB is currently unprofitable.

Growing Profit Margin: 2AB is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 2AB is unprofitable, and losses have increased over the past 5 years at a rate of 25.6% per year.

Accelerating Growth: Unable to compare 2AB's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 2AB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).


Return on Equity

High ROE: 2AB has a negative Return on Equity (-36.3%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/25 04:26
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Barinthus Biotherapeutics plc is covered by 5 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
James MolloyAlliance Global Partners
Yi ChenH.C. Wainwright & Co.
Matthew HarrisonMorgan Stanley